LIVE WEBINAR
Accelerating Preclinical Oncology Drug Development - A Comprehensive One-Stop Solution from Early Target Discovery to PCC Molecules
Navigating the complexities of preclinical oncology requires more than just isolated assays—it demands a seamless integration of discovery, modeling, and evaluation. Yet, many next-generation programs struggle to translate binders into clinical success due to a lack of highly predictive, human-relevant environments.
In this webinar, we introduce Cyagen’s end-to-end oncology CRO ecosystem, a one-stop engine for therapeutic innovation. From target discovery via our HUGO-Ab™ fully human antibody
DATE
9:00-10:00 AM (PDT)
LOCATION
Online | Zoom
Introduction & Summary
Navigating the complexities of preclinical oncology requires a seamless
integration of discovery, modeling, and evaluation. This webinar introduces Cyagen’s comprehensive suite of
CRO services designed to serve as your ultimate one-stop shop for oncology drug development. We provide a
continuous engine for therapeutic innovation, starting with target discovery through our state-of-the-art
HUGO-Ab™ fully human antibody platform, supported by customized in vitro models for early-stage target
validation. Crucially, the translation of next-generation treatments—such as monoclonal antibodies,
bispecifics, and CAR-T cell therapies—demands highly predictive in vivo environments. We will explore the
critical role of our advanced in vivo platforms, including severely immunodeficient NKG mice,
immune-humanized NKG models (HSC and PBMC), and humanized GEMM models in accurately evaluating in
vivo therapeutic efficacy. Furthermore, we will detail how specialized models, including FcRn mice for
precise pharmacokinetic (PK) profiling, integrate into a complete preclinical strategy. Join us to discover
how our end-to-end oncology capabilities can streamline your workflow and efficiently advance your pipeline
toward optimal PCC molecules.
Topic Covered
- End-to-End Oncology CRO Services: How a unified approach accelerates pipelines from target screening to IND-enabling studies
- End-to-End Oncology CRO Services: How a unified approach accelerates pipelines from target screening to IND-enabling studies
- Target Validation Support: Utilizing tailored overexpressing and reporter cell lines to support functional screening.
- Advanced In Vivo Models: The translational advantages of NKG immunodeficient mice alongside humanized immune system models (huHSC, huPBMC) for immune reconstitution.
- Efficacy & PK Profiling: Strategies for assessing antibody and CAR-T therapy efficacy (in vivo and ex vivo) and conducting robust pharmacokinetic studies using FcRn mice.
Who should attend:
- Researchers and scientists specializing in tumor biology, immuno-oncology, and targeted therapies.
- Professionals leading cancer drug development, CAR-T/NK research, and preclinical pharmacology.
- Biotech and pharma industry leaders seeking streamlined, comprehensive preclinical CRO partnerships.
- PhD/Master-level scientists focused on antibody discovery, translational in vivo models, and efficacy evaluation.
Attend this webinar to:
- Understand the strategic advantage of utilizing a unified preclinical oncology platform to reduce downstream screening burdens.
- Learn how to bridge the gap between binders and functionally robust PCC molecules.
- Explore real-world applications of humanized immune mice (HSC/PBMC) in evaluating the efficacy of immunotherapies and CAR-T therapies.
- Explore real-world applications of humanized immune mice (HSC/PBMC) in evaluating the efficacy of immunotherapies and CAR-T therapies.
Webinar Presenter
{{value.name}}
{{value.title}}
{{value.company}}
Discover Our Solutions
{{ value.label }}
{{ value.name }}
Explore
Request Information About This Webinar
Whether you're joining live or catching up later, fill out the form to receive materials or updates related to this webinar.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.